A prospective, multicenter, randomized, open-label, comparative study to evaluate the safety, tolerability, and efficacy of ertapenem sodium (MK0826) versus ticarcillin/clavulanate [ticarcillin/clavulanic acid] in the treatment of hospital-acquired pneumonia [nosocomial pneumonia], complicated intra-abdominal infections, and acute pelvic infections in pediatric patients

Trial Profile

A prospective, multicenter, randomized, open-label, comparative study to evaluate the safety, tolerability, and efficacy of ertapenem sodium (MK0826) versus ticarcillin/clavulanate [ticarcillin/clavulanic acid] in the treatment of hospital-acquired pneumonia [nosocomial pneumonia], complicated intra-abdominal infections, and acute pelvic infections in pediatric patients

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Ertapenem; Ticarcillin/clavulanic acid
  • Indications Bacterial infections; Intra-abdominal infections; Nosocomial pneumonia; Paediatric infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top